MedPath

Levobupivacaine

Generic Name
Levobupivacaine
Drug Type
Small Molecule
Chemical Formula
C18H28N2O
CAS Number
27262-47-1
Unique Ingredient Identifier
A5H73K9U3W
Background

Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted

pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. In particular, the specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and possesses a greater length of action in comparison to bupivacaine. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children. When administered appropriately, the occurrence of adverse effects is not anticipated much if at all. In general, the majority of potential adverse effects are predominantly associated with inappropriate administration methods that may cause systemic exposure and/or toxicity associated with overexposure to an anesthetic. Regardless, allergic reactions may also occur - although only rarely.

Indication

For the production of local or regional anesthesia for surgery and obstetrics, and for post-operative pain management

Associated Conditions
Pain
Associated Therapies
Local Anaesthesia therapy, Lumbar epidural anesthesia therapy

Interpectoral-pectoserratus Plane Block for Minimally Invasive Aortic Valve Replacement Via Right Anterior Minithoracotomy

Phase 4
Not yet recruiting
Conditions
Analgesic Effect
Interventions
First Posted Date
2024-04-17
Last Posted Date
2024-04-17
Lead Sponsor
Algemeen Ziekenhuis Maria Middelares
Target Recruit Count
144
Registration Number
NCT06369870
Locations
🇧🇪

AZ Maria Middelares, Ghent, East-Flanders, Belgium

Programmed Intermittent Epidural Bolus (PIEB) Techniques for Labour Analgesia

Phase 4
Completed
Conditions
Analgesia
Labor Pain
Obstetric Pain
Interventions
First Posted Date
2024-02-20
Last Posted Date
2024-11-01
Lead Sponsor
Hamad Medical Corporation
Target Recruit Count
136
Registration Number
NCT06266767
Locations
🇶🇦

Hamad Medical Corporation (HMC), Doha, Qatar

Adding Ketamine to Levobupivacaine in Paravertebral Block in Thoracotomy

Phase 4
Completed
Conditions
Ketamine
Levobupivacaine
Paravertebral Block
Acute Pain
Chronic Pain
Interventions
First Posted Date
2023-08-25
Last Posted Date
2024-02-13
Lead Sponsor
Tanta University
Target Recruit Count
60
Registration Number
NCT06011746
Locations
🇪🇬

Tanta University, Tanta, El-Gharbia, Egypt

Echo-guided Transverse Abdominal Plane Block (TAP) in Anterior Lumbar Arthrodesis (ALIF)

Not Applicable
Recruiting
Conditions
Fusion of Spine, Lumbar Region
Interventions
Other: Placebo Tap block
First Posted Date
2023-08-21
Last Posted Date
2025-04-01
Lead Sponsor
Clinique Saint Jean, France
Target Recruit Count
80
Registration Number
NCT06002217
Locations
🇫🇷

Clinique St jean sud de france, Montpellier, France

Caudal Block for Inguinal Hernioplasty in Children

Phase 3
Completed
Conditions
Postoperative Pain
Interventions
Drug: General anesthesia
Procedure: Inguinal hernioplasty
First Posted Date
2023-07-24
Last Posted Date
2024-12-04
Lead Sponsor
University of Novi Sad
Target Recruit Count
70
Registration Number
NCT05958589
Locations
🇷🇸

Institute for health care of children and youth of Vojvodina, Novi Sad, Vojvodina, Serbia

Evaluate Efficacy Levobupivacaine 0.125% Versuss Ropivacaine 0.2% in Hemodynamic Alterations in Labor and Fetal Repercussions

Phase 4
Not yet recruiting
Conditions
Hemodynamic Instability
Epidural
Fetal Cardiac Disorder
Pregnancy
Interventions
First Posted Date
2023-05-26
Last Posted Date
2023-05-26
Lead Sponsor
Althaia Xarxa Assistencial Universitària de Manresa
Target Recruit Count
40
Registration Number
NCT05877131
Locations
🇪🇸

Althaia Xarxa Assitensial i Universitaria Manresa, Manresa, Barcelona, Spain

Long-term Outcomes of Breast Cancer Patients After Wound Infiltration Analgesia

Phase 4
Completed
Conditions
Health Related Quality of Life
Hand Strength
Chronic Shoulder Pain
Surgical Wound Infiltration
Lymph Node Dissection
Postoperative Analgesia
Breast Cancer Female
Interventions
First Posted Date
2023-04-26
Last Posted Date
2023-04-28
Lead Sponsor
Osijek University Hospital
Target Recruit Count
120
Registration Number
NCT05829707

The Immune Response of Breast Cancer Patients Treated With Levobupivacaine Using Paravertebral or Superficial Chest Blocks

Not Applicable
Active, not recruiting
Conditions
Paravertebral Block
Levobupivacaine
Pectoralis and Serratus Plane Nerve Blocks
Breast Cancer
Immunologic Suppression
Interventions
Procedure: Paravertebral nerve block (PVB)
Procedure: Pectoralis and Serratus Plane Nerve Blocks (PECS 2)
Device: Regional anesthetic technique with ultrasound guidance
Device: Regional anesthetic technique with peripheral nerve stimulation.
Procedure: General anesthesia
First Posted Date
2023-04-18
Last Posted Date
2025-04-02
Lead Sponsor
University of Rijeka
Target Recruit Count
100
Registration Number
NCT05816538
Locations
🇭🇷

University hospital centre Rijeka, Rijeka, Croatia

Comparing General Anesthesia With Single Injection Peribulbar Block With 3 Different Drugs

Not Applicable
Completed
Conditions
Pediatric Squint Surgeries
Interventions
First Posted Date
2023-02-14
Last Posted Date
2025-04-23
Lead Sponsor
Research Institute of Ophthalmology, Egypt
Target Recruit Count
55
Registration Number
NCT05728151
Locations
🇪🇬

Research Institute of Ophthalmology, Giza, Egypt

Local Wound Anesthesia in Spine Surgery

Not Applicable
Completed
Conditions
Surgical Wound
Orthopedic Disorder of Spine
Interventions
Drug: Infiltration with NaCl
Drug: Infiltration with Ropivacain
First Posted Date
2023-01-23
Last Posted Date
2023-06-28
Lead Sponsor
Balgrist University Hospital
Target Recruit Count
150
Registration Number
NCT05693454
Locations
🇨🇭

Balgrist University Hospital, Zurich, Switzerland

© Copyright 2025. All Rights Reserved by MedPath